PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Facing challenges, Deciphera cuts workforce by a third

Deciphera is regrouping after Qinlock failed to outperform standard of care in a Phase 3 study testing the drug as a second-line treatment for GIST. Sales of the drug in the fourth-line setting have been modest, reaching $21.7 million in the third quarter.

Wall Street analysts viewed the restructuring as a necessary step, and the company’s shares jumped 12% on Tuesday. The savings will allow Deciphera to conserve enough cash to operate though 2024 while focusing on two experimental cancer drugs it deems most promising for future growth: vimseltinib and another drug called DCC-3116.

A Phase 3 study of vimseltinib, an oral medicine for tenosynovial giant cell tumors, should start before the end of the year, Deciphera said.

DCC-3116, intended to treat tumors with certain types of mutations, is in an earlier stage. The company plans to release data from a Phase 1 dosing study next year.

Deciphera isn’t the only biotech company cutting jobs this fall. Theravance, Esperion and FibroGen have all announced workforce reductions in recent months. Deciphera said it will take a charge of about $32 million in the fourth quarter for the restructuring.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40